- Home
- ABEO vs CLLS Comparison
ABEO vs CLLS Comparison
Compare ABEO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- CLLS
- Stock Information
- Founded
- ABEO 1974
- CLLS 1999
- Country
- ABEO United States
- CLLS France
- Employees
- ABEO 136
- CLLS N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- ABEO Health Care
- CLLS Health Care
- Exchange
- ABEO Nasdaq
- CLLS Nasdaq
- Market Cap
- ABEO 289.2M
- CLLS 299.0M
- IPO Year
- ABEO 1980
- CLLS 2007
- Fundamental
- Price
- ABEO $5.69
- CLLS $3.16
- Analyst Decision
- ABEO Strong Buy
- CLLS Buy
- Analyst Count
- ABEO 6
- CLLS 1
- Target Price
- ABEO $18.17
- CLLS $4.00
- AVG Volume (30 Days)
- ABEO 765.1K
- CLLS 71.4K
- Earning Date
- ABEO 11-13-2025
- CLLS 11-03-2025
- Dividend Yield
- ABEO N/A
- CLLS N/A
- EPS Growth
- ABEO N/A
- CLLS N/A
- EPS
- ABEO 0.99
- CLLS N/A
- Revenue
- ABEO $400,000.00
- CLLS $63,438,000.00
- Revenue This Year
- ABEO N/A
- CLLS N/A
- Revenue Next Year
- ABEO $324.71
- CLLS $66.76
- P/E Ratio
- ABEO $5.66
- CLLS N/A
- Revenue Growth
- ABEO N/A
- CLLS 223.09
- 52 Week Low
- ABEO $3.93
- CLLS $1.10
- 52 Week High
- ABEO $7.54
- CLLS $3.35
- Technical
- Relative Strength Index (RSI)
- ABEO 31.90
- CLLS 64.57
- Support Level
- ABEO $5.52
- CLLS $2.99
- Resistance Level
- ABEO $5.82
- CLLS $3.20
- Average True Range (ATR)
- ABEO 0.28
- CLLS 0.17
- MACD
- ABEO -0.16
- CLLS 0.03
- Stochastic Oscillator
- ABEO 11.11
- CLLS 77.76
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.